Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Core Viewpoint - Instil Bio has entered into a definitive agreement to in-license ex-China development and commercialization rights for ImmuneOnco's bispecific antibody IMM2510 and next-generation anti-CTLA-4 antibody IMM27M, indicating a strategic expansion in their oncology pipeline [1][4]. Group 1: Product Details - IMM2510 is a bispecific antibody that combines an anti-PD-L1 antibody with a VEGF receptor "trap," designed to enhance tumor penetration and improve tumor killing through enhanced antibody-dependent cellular cytotoxicity (ADCC) [2]. - IMM2510 has shown promising results in a dose-escalation clinical trial for advanced solid tumors, including responses in patients with squamous non-small cell lung cancer who had previously failed PD-1 inhibitors [2]. - IMM27M is a next-generation anti-CTLA-4 antibody with enhanced ADCC activity, aimed at improving efficacy and reducing toxicity compared to first-generation anti-CTLA-4 antibodies, and has also demonstrated anti-tumor activity in advanced solid tumors [3]. Group 2: Agreement Terms - Under the agreement, Instil's subsidiary will gain global rights for the development and commercialization of IMM2510 and IMM27M outside Greater China, while ImmuneOnco retains rights in Greater China, including Taiwan, Macau, and Hong Kong [4]. - ImmuneOnco will receive an upfront payment and potential near-term payments of up to $50 million, along with additional development, regulatory, and commercial milestones exceeding$2 billion, plus royalties on global ex-China sales [4]. Group 3: Company Background - Instil Bio is a clinical-stage biopharmaceutical company focused on developing novel therapies, with IMM2510 as its lead asset targeting multiple solid tumor cancers [5]. - ImmuneOnco is a clinical-stage biotech company dedicated to discovering and developing biologics for cancer treatment, currently advancing multiple assets, including one in phase III [6].